Cargando…

Role of Glucose Metabolism Reprogramming in the Pathogenesis of Cholangiocarcinoma

Cholangiocarcinoma (CCA) is one of the most lethal cancers, and its rate of occurrence is increasing annually. The diagnoses of CCA patients remain elusive due to the lack of early symptoms and is misdiagnosed as HCC in a considerable percentage of patients. It is crucial to explore the underlying m...

Descripción completa

Detalles Bibliográficos
Autores principales: Pant, Kishor, Richard, Seth, Peixoto, Estanislao, Gradilone, Sergio A
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7146077/
https://www.ncbi.nlm.nih.gov/pubmed/32318579
http://dx.doi.org/10.3389/fmed.2020.00113
_version_ 1783520117117681664
author Pant, Kishor
Richard, Seth
Peixoto, Estanislao
Gradilone, Sergio A
author_facet Pant, Kishor
Richard, Seth
Peixoto, Estanislao
Gradilone, Sergio A
author_sort Pant, Kishor
collection PubMed
description Cholangiocarcinoma (CCA) is one of the most lethal cancers, and its rate of occurrence is increasing annually. The diagnoses of CCA patients remain elusive due to the lack of early symptoms and is misdiagnosed as HCC in a considerable percentage of patients. It is crucial to explore the underlying mechanisms of CCA carcinogenesis and development to find out specific biomarkers for early diagnosis of CCA and new promising therapeutic targets. In recent times, the reprogramming of tumor cells metabolism has been recognized as a hallmark of cancer. The modification from the oxidative phosphorylation metabolic pathway to the glycolysis pathway in CCA meets the demands of cancer cell proliferation and provides a favorable environment for tumor development. The alteration of metabolic programming in cancer cells is complex and may occur via mutations and epigenetic modifications within oncogenes, tumor suppressor genes, signaling pathways, and glycolytic enzymes. Herein we review the altered metabolism in cancer and the signaling pathways involved in this phenomena as they may affect CCA development. Understanding the regulatory pathways of glucose metabolism such as Akt/mTOR, HIF1α, and cMyc in CCA may further develop our knowledge of this devastating disease and may offer relevant information in the exploration of new diagnostic biomarkers and targeted therapeutic approaches for CCA.
format Online
Article
Text
id pubmed-7146077
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-71460772020-04-21 Role of Glucose Metabolism Reprogramming in the Pathogenesis of Cholangiocarcinoma Pant, Kishor Richard, Seth Peixoto, Estanislao Gradilone, Sergio A Front Med (Lausanne) Medicine Cholangiocarcinoma (CCA) is one of the most lethal cancers, and its rate of occurrence is increasing annually. The diagnoses of CCA patients remain elusive due to the lack of early symptoms and is misdiagnosed as HCC in a considerable percentage of patients. It is crucial to explore the underlying mechanisms of CCA carcinogenesis and development to find out specific biomarkers for early diagnosis of CCA and new promising therapeutic targets. In recent times, the reprogramming of tumor cells metabolism has been recognized as a hallmark of cancer. The modification from the oxidative phosphorylation metabolic pathway to the glycolysis pathway in CCA meets the demands of cancer cell proliferation and provides a favorable environment for tumor development. The alteration of metabolic programming in cancer cells is complex and may occur via mutations and epigenetic modifications within oncogenes, tumor suppressor genes, signaling pathways, and glycolytic enzymes. Herein we review the altered metabolism in cancer and the signaling pathways involved in this phenomena as they may affect CCA development. Understanding the regulatory pathways of glucose metabolism such as Akt/mTOR, HIF1α, and cMyc in CCA may further develop our knowledge of this devastating disease and may offer relevant information in the exploration of new diagnostic biomarkers and targeted therapeutic approaches for CCA. Frontiers Media S.A. 2020-04-03 /pmc/articles/PMC7146077/ /pubmed/32318579 http://dx.doi.org/10.3389/fmed.2020.00113 Text en Copyright © 2020 Pant, Richard, Peixoto and Gradilone. http://creativecommons.org/licenses/by/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Medicine
Pant, Kishor
Richard, Seth
Peixoto, Estanislao
Gradilone, Sergio A
Role of Glucose Metabolism Reprogramming in the Pathogenesis of Cholangiocarcinoma
title Role of Glucose Metabolism Reprogramming in the Pathogenesis of Cholangiocarcinoma
title_full Role of Glucose Metabolism Reprogramming in the Pathogenesis of Cholangiocarcinoma
title_fullStr Role of Glucose Metabolism Reprogramming in the Pathogenesis of Cholangiocarcinoma
title_full_unstemmed Role of Glucose Metabolism Reprogramming in the Pathogenesis of Cholangiocarcinoma
title_short Role of Glucose Metabolism Reprogramming in the Pathogenesis of Cholangiocarcinoma
title_sort role of glucose metabolism reprogramming in the pathogenesis of cholangiocarcinoma
topic Medicine
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7146077/
https://www.ncbi.nlm.nih.gov/pubmed/32318579
http://dx.doi.org/10.3389/fmed.2020.00113
work_keys_str_mv AT pantkishor roleofglucosemetabolismreprogramminginthepathogenesisofcholangiocarcinoma
AT richardseth roleofglucosemetabolismreprogramminginthepathogenesisofcholangiocarcinoma
AT peixotoestanislao roleofglucosemetabolismreprogramminginthepathogenesisofcholangiocarcinoma
AT gradilonesergioa roleofglucosemetabolismreprogramminginthepathogenesisofcholangiocarcinoma